Compounds > moxaprindine
Page last updated: 2024-11-06

moxaprindine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

moxaprindine: structure given in UD 31:185i [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID68699
CHEMBL ID2104713
SCHEMBL ID1813382
MeSH IDM0080787

Synonyms (17)

Synonym
moxaprindine
n,n-diethyl-n'-(1-methoxy-2,3-dihydro-1h-inden-2-yl)-n'-phenylpropane-1,3-diamine
53076-26-9
CHEMBL2104713
moxaprindine [inn]
5haf6qo904 ,
moxaprindinum
einecs 258-347-0
1,3-propanediamine, n-(2,3-dihydro-1-methoxy-1h-inden-2-yl)-n',n'-diethyl-n-phenyl-
moxaprindina
moxaprindinum [inn-latin]
unii-5haf6qo904
n,n-diethyl-n'-(1-methoxy-2-indanyl)-n'-phenyl-1,3-propanediamine
moxaprindina [inn-spanish]
SCHEMBL1813382
Q27262185
DTXSID50866299

Research Excerpts

Overview

Moxaprindine is a promising new antiarrhythmic drug for the treatment of ventricular arrhythmias. Its value and safely in the chronic oral treatment of these arrh rhythmias remain to be established.

ExcerptReferenceRelevance
"Moxaprindine is a powerful antiarrhythmic agent which deserves further assessment in long term studies."( The efficacy of intravenous moxaprindine on ventricular ectopic activity.
Guillaume, D; Kulbertus, H; Mary-Rabine, L; Waleffe, A, 1980)		1.28
"Moxaprindine is a promising new antiarrhythmic drug for the treatment of ventricular arrhythmias, but its value and safely in the chronic oral treatment of these arrhythmias remain to be established."( Moxaprindine in the acute treatment of ventricular arrhythmias in patients with cardiovascular disease.
Kesteloot, H; Staessen, J, 1981)		2.43

Pharmacokinetics

ExcerptReferenceRelevance
" Moxaprindine and aprindine are similar in several of their pharmacokinetic characteristics."( Pharmacokinetic study of aprindine and moxaprindine in dogs.
Breekpot, F; de Suray, JM; Lavis, A, 1981)		1.44

Dosage Studied

ExcerptRelevanceReference
" The sinus rate was slowed at every dosage level."( Moxaprindine in the acute treatment of ventricular arrhythmias in patients with cardiovascular disease.
Kesteloot, H; Staessen, J, 1981)		1.71
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.50 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
aprindine
Aprindine: A class Ib anti-arrhythmia agent used to manage ventricular and supraventricular arrhythmias.		3.2160indanes
thymidine
[no description available]		1.9610pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
metabolite;
mouse metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Arrhythmia
[description not available]		02.6530
Arrhythmias, Cardiac
Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.		02.6530
Rheumatoid Arthritis
[description not available]		01.9610
Chronic Kidney Failure
[description not available]		01.9610
Cirrhosis, Liver
[description not available]		01.9610
Arthritis, Rheumatoid
A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.		01.9610
Kidney Failure, Chronic
The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.		01.9610
Liver Cirrhosis
Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.		01.9610